Trevena, Inc. Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain

Published: Nov 14, 2012

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the successful completion of a Phase I first-in-human clinical trial of TRV130. Trevena is developing TRV130 for the intravenous treatment of acute moderate-to-severe post-operative pain. The drug was safe and generally well-tolerated in this study, with pharmacodynamic effects recapitulating its exciting preclinical profile. The next clinical study of TRV130 will investigate analgesic efficacy and tolerability, and will include intravenous morphine, a gold-standard post-operative analgesic, as a comparator.

Back to news